ABOS•Acumen Pharmaceuticals prepaid approximately $23.3 million of obligations under its K2 HealthVentures loan agreement on November 5, 2026, using cash on hand. The payment terminated the agreement and released all liens and security interests.
Acumen Pharmaceuticals prepaid all obligations under its K2 HealthVentures Loan Agreement for approximately $23.3 million on November 5, 2026, using cash on hand. The payoff included principal, accrued interest, fees and expenses, including a $1.6 million final payment fee.
The loan agreement's termination ended the lender's conversion right and released all liens and security interests. The term loan had been scheduled to mature on November 1, 2027.
